XWPharma Secures $205 M Valiloxybate Deal with Avadel
CompanyDeals

XWPharma Secures $205 M Valiloxybate Deal with Avadel

FDA Launches “Green List” to Shield U.S. Markets from Unsafe GLP‑1 APIs
Policy / Regulatory

FDA Launches “Green List” to Shield U.S. Markets from Unsafe GLP‑1 APIs

InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL
CompanyDrug

InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL

Regenelead Secures NMPA Approval for RGL‑305 Cell Therapy in Advanced Malignant Tumors
CompanyDrug

Regenelead Secures NMPA Approval for RGL‑305 Cell Therapy in Advanced Malignant Tumors

Takeda Secures FDA Approval for VONVENDI’s Expanded Use in Adult and Pediatric VWD
CompanyDrug

Takeda Secures FDA Approval for VONVENDI’s Expanded Use in Adult and Pediatric VWD

QuantumPharm XtalPi Secures Phase I Approval for PEP08, a Next‑Generation PRMT5 Inhibitor
CompanyDrug

QuantumPharm XtalPi Secures Phase I Approval for PEP08, a Next‑Generation PRMT5 Inhibitor

Escugen and Huahui Health Form Exclusive Partnership to Develop First‑in‑Class ADC for Solid Tumors
CompanyDeals

Escugen and Huahui Health Form Exclusive Partnership to Develop First‑in‑Class ADC for Solid Tumors

NHSA Releases Draft Regulations to Tighten Medical Insurance Funds Oversight
Policy / Regulatory

NHSA Releases Draft Regulations to Tighten Medical Insurance Funds Oversight

Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies
CompanyDeals

Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies

Junshi Biosciences' JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial
CompanyDrug

Junshi Biosciences’ JS005 IL‑17A Antibody Shows Promise in Phase III Psoriasis Trial

Hengrui’s RSS0393 PDE4 Inhibitor Approved for Atopic Dermatitis Clinical Trial
CompanyDrug

Hengrui’s RSS0393 PDE4 Inhibitor Approved for Atopic Dermatitis Clinical Trial

Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH
CompanyDrug

Hengrui’s HRS‑4729 GLP‑1 Triple Agonist Receives NMPA Approval for MASLD & MASH